Brief: BeyondSpring Announces Final Positive Data From The Protective-1 Phase 3 CIN Program Of Plinabulin As A Single Agent Compared To Pegfilgrastim At ASCO meeting
10/06/2021 12:21
June 10 (Reuters) - Beyondspring Inc BYSI.O :
* BEYONDSPRING ANNOUNCES FINAL POSITIVE DATA FROM THE
PROTECTIVE-1
PHASE 3 CIN PROGRAM OF PLINABULIN AS A SINGLE AGENT COMPARED TO
PEGFILGRASTIM AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY
(ASCO) ANNUAL MEETING
* BEYONDSPRING INC - DATA FURTHER SUPPORTS PLINABULIN'S FAST
ONSET
OF ACTION AND CIN PREVENTION BENEFIT IN WEEK 1 FOLLOWING
CHEMOTHERAPY
Source text for Eikon: ID:nGNX2L3HzN
Further company coverage: BYSI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beyondspring
See all newsBrief: Beyondspring Inc Entered Into Open Market Sale Agreement Under Which Co May Offer And Sell Up To 9.2 Million Ordinary Shares
Brief: Beyondspring Announces FDA Fast Track Designation For Plinabulin In Post-Ici Non-Squamous Nsclc And Strategic Transaction To Advance Global Phase 3 Dublin-4 Trial Toward Planned Interim Analysis
NASDAQ RESUMED AT 12:26 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:21 PM
Brief: Beyondspring Announces Leadership Transition To Deliver Focused Execution On Its Confirmatory Dublin-4 Program And Long-Term Value